Osborne M P, Rosen P P
Department of Surgery, New York Hospital-Cornell University Medical Center; Strang Cancer Prevention Center, New York.
Oncology (Williston Park). 1994 Aug;8(8):25-31; discussion 35-6, 39-42.
The presence and number of breast cancer micrometastases in the bone marrow at the time of diagnosis or initial treatment appear to predict early distant relapse. Immunologic techniques to detect such bone micrometastases, in combination with traditional prognostic variables, such as axillary lymph node status and tumor diameter, may allow for the identification of patients at high risk of systemic disease, who may benefit from adjuvant systemic chemotherapy. Immunofluorescent and immunochemical monoclonal antibody techniques have similar sensitivity in the detection of cancer cells in bone marrow. Future research is needed to develop more specific monoclonal antibodies and to determine the characteristics of the primary tumor that correlate with bone marrow micrometastasis, as well as the characteristics of micrometastases that correlate with recurrence.
诊断或初始治疗时骨髓中乳腺癌微转移灶的存在及数量似乎可预测早期远处复发。检测此类骨微转移灶的免疫技术，与传统预后变量（如腋窝淋巴结状态和肿瘤直径）相结合，可能有助于识别有发生全身疾病高风险的患者，这些患者可能从辅助全身化疗中获益。免疫荧光和免疫化学单克隆抗体技术在检测骨髓癌细胞方面具有相似的灵敏度。未来需要开展研究以开发更具特异性的单克隆抗体，并确定与骨髓微转移相关的原发性肿瘤特征，以及与复发相关的微转移灶特征。
